Clinical significance of osteopontin in esophageal squamous cell carcinoma: Comparison with common tumor markers

Oncology

Volumn 68, Issue 2-3, 2005, Pages 285-292

  Shimada, Yutaka ^a   Watanabe, Go ^a   Kawamura, Junichiro ^a   Soma, Toshiya ^a   Okabe, Michio ^a   Ito, Tetsuo ^a   Inoue, Harutaka ^a   Kondo, Masato ^a   Mori, Yukiko ^a   Tanaka, Eiji ^a   Imamura, Masayuki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Esophageal cancer; Lymph node metastasis; Osteopontin; Prognosis

Indexed keywords

CYTOKERATIN 19 FRAGMENT; OSTEOPONTIN; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER; ANTIGEN CYFRA21.1; KERATIN; SERINE PROTEINASE INHIBITOR; SIALOGLYCOPROTEIN; SPP1 PROTEIN, HUMAN; SQUAMOUS CELL CARCINOMA RELATED ANTIGEN; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; ENZYME IMMUNOASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TUMOR VOLUME; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; ESOPHAGUS TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; SURVIVAL;

AGED; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; KERATINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SERPINS; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 23844455265     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086961     Document Type: Article

References (39)

1. Vizcaino AP, Moreno V, Lambert R, Parkin DM: Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99:860-868.
2. Blot WJ, McLaughlin JK: The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:2-8.
3. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van den Brendt PA: Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645-654.
4. Senger DR, Wirth DF, Hynes RO: Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979;16:885-893.
5. Senger DR, Perruzzi CA: Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Res 1985;45:5818-5823.
6. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF: Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 1994;54:832-837.
7. Oates AJ, Barraclough R, Rudland PS: The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997;17:1-15.
8. Weber GF: The metastasis gene osteopontin: A candidate target for cancer therapy. Biochim Biophys Acta 2001;1552:61-85.
9. Crawford HC, Matrisian LM, Liaw L: Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998;58:5206-5215.
10. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997;3:605-611.
11. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E: Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998;79:127-132.
12. Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y: Expression of osteopontin in human glioma. Its correlation with malignancy. Lab Invest 1995;72:55-63.
13. Devoll RE, Li W, Woods KV, Pinero GJ, Butler WT, Farach-Carson MC, Happonen RP: Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. J Oral Pathol Med 1999;28:97-101.
14. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC: Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-1679.
15. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF: Plasma osteopontin. Association with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002;95:506-512.
16. Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzer R, Scheider PM, Salonga D, Holscher AH, Danenberg PV: Osteopontin but not osteonectin messenger RNA expression is a prognostic merker in curatively resected non-small cell lung cancer. Clin Cancer Res 2004;10:1588-1596.
17. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-423.
18. Agrawal D, Chen T, Irby R, Quackenbush, Chambers AF, Szabo M, Cantor, Coppola D, Yeatman TJ: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002;94:513-521.
19. Le QT, Sutphin PD, Raychaudhuri S, Yu SCT, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ: Idenftification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003;9:59-67.
20. Imamura M, Shimada Y, Kanda Y, Fukumoto M, Yanagibashi K, Miyahara T, Tobe T: Usefulness of preoperative low dose cisplatin treatment for advanced oesophageal cancer. Surg Today 1992;22:409-415.
21. Imamura M, Shimada Y, Kanda Y, Miyahara T, Hashimoto M, Tobe T, Arai T, Hatano Y: Hemodynamic changes after resection of the thoracic duct for en bloc resection of oesophageal cancer. Surg Today 1992;22:226-232.
22. Nishimura Y, Ono K, Imamura M, Hiraoka M, Takahashi M, Abe M, Ohishi K, Yanagibashi K, Tobe T: Postoperative radiation therapy for esophageal cancer. Radiat Med 1989;7:88-94.
23. Cox DR: Regression models and life tables. J R Stat Soc [B] 1972;34:187-220.
24. Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T: Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 2000;89:1677-1683.
25. Shimada H, Nabeya Y, Tagawa M, Okazumi S, Matsubara H, Kadomatsu K, Muramatsu T, Ikematsu S, Sakuma S, Ochiai T: Preoperative midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 2003;94:628-632.
26. Denhardt DT, Lopez CA, Rollo EE, Hwang SM, An XR, Walther SE: Osteopontin-induced modifications of cellular functions. Ann NY Acad Sci 1995;760:127-142.
27. Brockmann JG, Nottberg HS, Glodny B, Heinnecke A, Senninger NJ: Cyfra 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 2000;6:4249-4252.
28. Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T: Cyfra 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 1997;79:1647-1655.
29. Kawaguchi H, Ohno S, Miyazaki M, Hashimoto K, Egashira A, Saeki H, Watanabe M, Sugimachi K: Cyfra 21-1 determination in patients with esophageal squamous cell carcinoma. Cancer 2000;89:1413-1417.
30. Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki S, Watanabe S: Cyfra 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus 1998;11:31-39.
31. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Miyazawa Y, Shiratori T, Hayashi H, Gunji Y, Ochiai T: Prognostic significance of Cyfra 21-1 in patients with esophageal squamous cell carcinoma. J Am Coll Surg 2003;196:573-578.
32. Kato H, Torigoe T: Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977;40:1621-1628.
33. Duk JM, Groenier KH, de Bruijn HW, Hollema H, ten Hoor KA, van der Zee AG, Aalders JG: Pretreatment serum squamous cell carcinoma antigen: A newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 1996;14:111-118.
34. Molina R, Torres MD, Moragas M, Perez-Villa J, Filella X, Jo J, Farrus B, Gimenez N, Traserra J, Ballesta AM: Prognostic significance of SCC antigen in the serum of patients with head and neck cancer. Tumour Biol 1996;17:81-89.
35. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, Kobayashi S, Hayashi H, Ochiai T: Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 2003;133:486-494.
36. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP: Carcinoembryonic antigen, a human tumor markler, functions as an intercellular adhesion molecule. Cell 1989;57:327-334.
37. Pignatelli M, Durbin H, Bodmer WF: Carcinoembryonic antigen functions as an accessory adhesion melecule mediating colon epithelial cell-collagen interactions. Proc Natl Acad Sci USA 1990;87:1541-1545.
38. Kim TH, Ajani JA, Ota DM, Lynch P, Roth JA: Value of serial Carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer 1995;75:451-456.
39. Clark GWB, Ireland AP, Hagen JA, Collard JM, Peters JH, DeMeester TR: Carcinoembryonic antigen measurements in the management of esophageal cancer: An indicator of subclinical recurrence. Am J Surg 1995;170:597-601.